Feline Leukaemia Virus gp70 Antibody (C11D8) [DyLight 650]

• Reactivity: V-Vi
• Applications: WB, Flow, IHC, IP
• Clone: C11D8
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: DyLight 650

Feline Leukaemia Virus gp70 Antibody (C11D8) [DyLight 650] Summary

• Immunogen: Made to Viral FELINE LEUKAEMIA VIRUS gp70
• Specificity: NB100-65565 recognizes the gp85/gp70 envelope glycoprotein of feline leukaemia virus. The antibody specifically recognizes the epitope defined by amino acids 214-218 of the gp70 sequence (aa MGPNL). Some weak cross-reactivity with the sequence MGPLL found in the FeLV p15e membrane protein may also occur. This antibody effectively neutralises all three FeLV subgroups (A,B and C).
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for Feline Leukaemia Virus gp70 Antibody (C11D8) [DyLight 650]

• Env polyprotein
• Feline Leukemia Virus glycoprotein 70
• Glycoprotein gp70 [Precursor]
• GP70 envelope protein
• gp70 protein (SU)
• p15E protein (TM)
• p15E protein

Background

FeLV is a retrovirus (family Oncovirinae) that can cause severe immunosuppression, severe non regenerative anemia, and a variety of neoplasms. The 3 main subtypes (FeLVA, FeLVB and FeLVC) may act independently or together to cause a variety of diseases. The major envelope glycoprotein (gp70) is used to bind to target cells and varies with the FeLV subtype.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.